---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-23-000023"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2023-03-20T23:59:59+00:00"
generated_at: "2026-06-17T22:54:21.065137+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio provides N-803 BLA update with May 23 PDUFA, reports NSCLC OS data, and notes S1800D closure

## Summary
- BLA for N-803+BCG in BCG-unresponsive NMIBC with CIS; PDUFA date May 23, 2023; approval uncertain.
- QUILT 3.055 NSCLC pooled analysis (N=86) shows median OS 13.9 months vs historical 6-7.5 months.
- SWOG/NCI S1800D study (N-803+pembrolizumab) closed early for not meeting 60% disease control at 12 weeks.
- Company exploring partnering for N-803 intravesical commercialization and potential financing from Executive Chairman.
- Board appointed Cheryl L. Cohen as Lead Independent Director.

## SEC filing metadata
- accession: 0001326110-23-000023
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2023-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000023/0001326110-23-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611023000023/ibrx-20230320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-23-000023
- JSON: https://secwatch.observer/filing/0001326110-23-000023.json
- Plain text: https://secwatch.observer/filing/0001326110-23-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.